Dinuclear copper(II) perchlorate complexes with 6-(benzylamino)purine derivatives: Synthesis, X-ray structure, magnetism and antiradical activity

The reactions of Cu(ClO4)2·6H2O with 6-(benzylamino)purine derivatives in a stoichiometric 1:2 metal-to-ligand ratio led to the formation of penta-coordinated dinuclear complexes of the formula [Cu2(μ-L1–8)4(ClO4)2](ClO4)2·nsolv, where L1 = 6-(2-fluorobenzylamino)purine (complex 1), L2 = 6-(3-fluorobenzylamino)purine (2), L3 = 6-(4-fluorobenzylamino)purine (3), L4 = 6-(2-chlorobenzylamino)purine (4), L5 = 6-(3-chlorobenzylamino)purine (5), L6 = 6-(4-chlorobenzylamino)purine (6), L7 = 6-(3-methoxybenzylamino)purine (7) and L8 = 6-(4-methoxybenzylamino)purine (8); n = 0–4 and solv = H2O, EtOH or MeOH. All the complexes have been fully characterized by elemental analysis, FTIR, UV–Vis and EPR spectroscopy, and by magnetic and conductivity measurements. Variable temperature (80–300 K) magnetic susceptibility data of 1–8 showed the presence of a strong antiferromagnetic exchange interaction between two Cu(II) (S = 1/2) atoms with J ranging from −150.0(1) to −160.3(2) cm−1. The compound 6·4EtOH·H2O was structurally characterized by single crystal X-ray analysis. The Cu⋯Cu separation has been found to be 2.9092(8) Å. The antiradical activity of the prepared compounds was tested by in vitro SOD-mimic assay with IC50 in the range 8.67–41.45 μM. The results of an in vivo antidiabetic activity assay were inconclusive and the glycaemia in pre-treated animals did not differ significantly from the positive control.

A series of dinuclear Cu(II) complexes with 6-(benzylamino)purine derivatives of the composition [Cu2(μ-L1–8)4(ClO4)2](ClO4)2·nsolv have been prepared and fully characterized. Antiradical activity of the prepared compounds was estimated by in vitro SOD-mimic and in vivo antidiabetic tests.Figure optionsDownload as PowerPoint slide